奥马珠单抗治疗变应性鼻炎的疗效与安全性的Meta分析

邱昕; 王洪田

doi:10.13201/j.issn.1001-1781.2016.09.006

奥马珠单抗治疗变应性鼻炎的疗效与安全性的Meta分析

邱昕¹,
王洪田^1,2, ,

- 1. 解放军总医院耳鼻咽喉头颈外科(北京, 100853);
- 2. 解放军总医院海南分院耳鼻咽喉头颈外科

详细信息

通讯作者: 王洪田,E-mail:wht301@263.net

中图分类号: R765.21

收稿日期: 2015-12-28

Safety and efficacy of omalizumab for the treatment of allergic rhinitis: Meta-analysis of randomized clinical trials

QIU Xin¹,
WANG Hongtian^1,2, ,

- 1. Department of Otolaryngology-Head and Neck Surgery, Chinese PLA General Hospital, Beijing, 100853, China;
- 2. Department of Otolaryngology-Head and Neck Surgery, Hainan Branch of Chinese PLA General Hospital

More Information

Corresponding author: WANG Hongtian, E-mail: wht301@263.net

Received Date: 28 December 2015

摘要

摘要: 目的：分析奥马珠单抗针对变应性鼻炎患者的疗效和安全性，为临床治疗变应性鼻炎提供循证医学证据。方法：检索Pubmed、Medline、Cochrane、Embase等数据库，同时手工检索相关会议论文集、出版物及会议摘要等。检索年限自建库至2014年8月。检索词汇包括：变应性鼻炎、奥马珠单抗、疗效、安全性和随机对照试验，无语言限制。然后按照纳入和排除标准对文献进行筛选及质量评估，运用RevMan5.3统计学软件（Cochrane协作网站提供）对所提取的数据进行Meta分析。结果：共纳入9例随机对照实验。均为英文文献，纳入人数1 764例，实验组859例，对照组905例。Meta分析结果表明，应用奥马珠单抗治疗的实验组相比较应用安慰剂的对照组，在改善患者症状评分上差异有统计学意义（P<0.05），安全性差异无统计学意义（P<0.05），其WMD值和95%CI分别为总鼻炎症状评分（0.04，-0.10~0.19），流涕（-0.32，-0.44~-0.21），鼻塞（-0.33，-0.38~-0.27），鼻痒（-0.08，-0.25~0.09），喷嚏（-0.24，-0.27~-0.21），非鼻部症状（0.30，0.04~0.55）。结论：奥马珠单抗与安慰剂相比，能明显改善变应性鼻炎患者的症状，疗效较好，安全性良好。
- 奥马珠单抗 /
- 鼻炎,变应性 /
- Meta分析
Abstract: Objective: To assess the efficacy and safety of omalizumab in patients with allergic rhinitis(AR) in a meta-analysis of clinical trial results, and provide evidence for the clinical treatment of AR.Method: Pubmed, Medline, Cochrane and Embase were searched through August 2014 using the terms 'allergic rhinitis, omalizumab, efficacy, safety, and randomized controlled trial(RCT)'without language restriction. Relevant reviews, publications, and abstracts of meetings were also retrieved. RevMan5.3 software was used for meta-analysis after data extraction.Result: Nine RCTs were included(n=1764).Of the 1764 participants,859 patients were treated by omalizumab and the other 905 received a placebo.The meta-analysis revealed that patients treated with omalizumab had significantly reduced total and individual symptoms scorescompared with the placebo group(P<0.05). And there was no significantly differences in adverse events between placebo and omalizumab(P<0.05).The WMD rate and 95%CI were as follows:total nasal symptom scores(0.04,-0.10 to 0.19), rhinorrhea (-0.32, -0.44 to -0.21), nasal stuffiness(-0.33,-0.38 to -0.27), nasal itching (-0.08,-0.25 to 0.09), and sneezing(-0.24, -0.27 to -0.21), and non-nasal symptoms scores(0.30,0.04 to 0.55).Conclusion: Compared to the placebo,omalizumab can effectively and safely reduce symptoms scores of patients with AR.
- omalizumab /
- rhinitis, allergic /
- Meta-analysis

HTML全文

参考文献(14)

[1]	KULIG M,KLETTKE U,WAHN V,et al.Development of seasonal allergic rhinitis during the first 7years of life[J].J Allergy Clin Immunol,2000,106:832-839.
[2]	邱昕,王洪田.儿童鼻炎意见书:欧洲变态反应与临床免疫学会推荐[J].国际耳鼻咽喉头颈外科杂志,2015,39(2):116-121.
[3]	BROWNELL J,CASALE T B.Anti-IgE therapy[J].Immunol Allergy Clin North Am,2004,24:551-568.
[4]	OKUBO K,OGINO S,NAGAKURA T,et al.Omalizumab is effective and safe in the treatment of japanese cedar pollen-induced seasonal allergic rhinitis[J].Allergol Int,2006,55:379-386.
[5]	NAGAKURA T,OGINO S,OKUBO K,et al.Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis[J].Clin Exp Allergy,2007,38:329-337.
[6]	CHERVINSKY P,CASALE T,TOWNLEY R,et al.Omalizumab,an anti-IgE antibody,in the treatment of adults and adolescents with perennial allergic rhinitis[J].Ann Allergy Asthma Immunol,2003,91:160-167.
[7]	HANF G,NOGA O,CONNOR A,et al.Omalizumab inhibits allergen challenge-induced nasal response[J].Eur Respir J,2004,23:414-418.
[8]	HUMBERT M,BOULET L P,NIVEN R M,et al.Omalizumab therapy:patients who achieve greatest benefit for their asthma experience greatest benefit for rhinitis[J].Allergy,2009,64:81-84.
[9]	PINTO J M,MEHTA N,DETINEO M,et al.A randomized,double-blind,placebo-controlled trial of anti-IgE for chronic rhinosinusitis[J].Rhinology,2010,48:318-324.
[10]	THOMAS B,CONDEMIJ,LAFORCE C,et al.Effect of omalizumab on symptoms of seasonal allergic rhinitis[J].JAMA,2001,286:2956-2967.
[11]	VIGNOLA A M,HUMBERT M,BOUSQUET J,et al.Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis:SOLAR[J].Allergy,2004,59:709-717.
[12]	PRUSSIN C,GRIFFITH D T,BOESEL K M,et al.Omalizumab treatment downregulates dendritic cell FcεRI expression[J].J Allergy Clin Immunol,2003,112:1147-1154.
[13]	VICHYANOND P.Omalizumab in allergic diseases,a recent review[J].Asian Pac J Allergy Immunol,2011,29:209-219.
[14]	BAENA-CAGNANI C E,GÓMEZ R M.Current status of therapy with omalizumab in children[J].Curr Opin Allergy Clin Immunol,2014,14:149-154.